Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on CTI BioPharma, Raises Price Target to $9

Needham analyst Gil Blum maintains CTI BioPharma (NASDAQ:CTIC) with a Buy and raises the price target from $8 to $9.

August 9, 2022

1 minute read

Needham analyst Gil Blum maintains CTI BioPharma (NASDAQ:CTIC) with a Buy and raises the price target from $8 to $9.

‘A ransomware group is threatening to release Nvidia’s “most closely-guarded secrets” today unless the chipmaker meets their increasingly bizarre demands’ -TechCrunch Report

Today, 3:45 AM

https://techcrunch.com/2022/03/04/nvidia-ransomware-hackers-demands/

Today, 3:45 AM

Wells Fargo analyst Daniel Politzer maintains Caesars Entertainment (NASDAQ:CZR) with a Overweight and lowers the price target from $145 to $127.

Today, 3:45 AM

-Reuters https://www.reuters.com/business/retail-consumer/exclusive-seas-e-commerce-arm-shopee-shut-down-india-operations-statement-2022-03-28/

Today, 3:45 AM

Shiba Inu (CRYPTO: SHIB) saw its price spike after being listed by Robinhood Markets Inc (NASDAQ: HOOD) on Tuesday.